Xinyuan Real Estate Co. (XIN) Tops Q2 EPS Views; Issues Strong Outlook; Buys Suzhou Parcel for $42.6M
Tweet Send to a FriendGet Alerts XIN Hot Sheet
Trade XIN Now!
Xinyuan Real Estate Co. (NYSE: XIN) reported Q2 EPS of $0.94, $0.54 better than the analyst estimate of $0.40. Revenue for the quarter came in at $253.1 million versus the consensus estimate of $213.3 million.
Yesterday, August 9, 2012, the Company acquired a parcel of land In Suzhou with a total GFA of approximately 128,000 square meters at a cost of RMB270 million(US$42.6 million).
Sees Q3 2012 revenue of $225-$235 million, versus the consensus of $201.20 million.
Sees FY2012 revenue of $825-$845 million, versus the consensus of $771.30 million.
For earnings history and earnings-related data on Xinyuan Real Estate Co. (XIN) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Yesterday, August 9, 2012, the Company acquired a parcel of land In Suzhou with a total GFA of approximately 128,000 square meters at a cost of RMB270 million(US$42.6 million).
Sees Q3 2012 revenue of $225-$235 million, versus the consensus of $201.20 million.
Sees FY2012 revenue of $825-$845 million, versus the consensus of $771.30 million.
For earnings history and earnings-related data on Xinyuan Real Estate Co. (XIN) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Actuant Corp. (ATU) Tops Q3 EPS by 3c; Trims FY13 Outlook, Guides FY14
- UPDATE: Liberty Global (LBTYA) Interested in Kabel Deutschland - FT
- UPDATE: ViroPharma (VPHM) on the Move Following Takeover Chatter - Reuters
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Mergers and AcquisitionsRelated Entities
EarningsLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

